


WE CLAIM:

1. A compound according to Formula I:



wherein

X is N or CR^6 .

L is O, S, NR, or a bond;

R is H or C₁-C₆-alkyl;

R¹ is selected from the group consisting of C₁-C₆-alkyl, C₂-C₆-alkenyl, C₃-C₆-carbocyclyl, -(C₁-C₆-alkyl)(C₃-C₆-carbocyclyl), and -(C₁-C₆-alkyl)(C₃-C₆-cycloalkenyl) wherein

any alkyl in R^1 is straight or branched, and

R¹ is optionally substituted by 1 – 6 halo;

or when L is NR, then R and R¹ in combination with L represent a 3- to 6-membered heterocycloalkyl (wherein 1-4 ring members are independently selected from N, O, and S) optionally substituted by one or more R^A;

R² and R³ are independently selected from the group consisting of C₆-C₁₀-aryl, 5- to 10-membered heteroaryl (wherein 1-4 heteroaryl members are independently selected from N, O, and S), and 3- to 14-membered heterocycloalkyl (wherein 1-4 heterocycloalkyl members are independently selected from N, O, and S),

wherein R² and R³ are independently and optionally substituted by one or more substituents that are selected from the group consisting of R^A, OR^A, halo, -N=N- R^A, NR^AR^B, -(C₁-C₆-alkyl)NR^AR^B, -C(O)OR^A, -C(O)NR^AR^B, -OC(O)R^A, and -CN;

R^{2a} is absent or present and, if present, it is taken together with R² and the carbon atom to which they are attached to form a spiro-fused 5- to 6-membered carbocyclyl or heterocycloalkyl (wherein 1-4 carbocyclyl or heterocycloalkyl members are independently selected from N, O, and S),

and each bond $\equiv$ (a) represents a single bond and each bond $\equiv$ (b) represents a double bond;

wherein the spiro-fused 5- to 6-membered carbocyclyl or

heterocycloalkyl is optionally substituted by one or more R^A ;

and if R^{2a} is absent, then each bond $\equiv$ (a) represents a double bond and each bond $\equiv$ (b) represents a single bond;

R^4 , R^5 , and R^6 are independently selected from the group consisting of R^A , OR^A , halo, $NR^A R^B$, $-(C_1-C_6-alkyl)NR^A R^B$, $-C(O)OR^A$, $-C(O)NR^A R^B$, and $-OC(O)R^A$;

R^A and R^B are independently selected from the group consisting of H, $-CN$, $-hydroxy$, oxo , $C_1-C_6-alkyl$, $C_1-C_6-alkoxy$, $C_2-C_6-alkenyl$, $C_2-C_6-alkynyl$, NH_2 , $-S(O)_{0-2}-(C_1-C_6-alkyl)$, $-S(O)_{0-2}-(C_6-C_{10}-aryl)$, $-C(O)(C_1-C_6-alkyl)$, $-C(O)(C_3-C_{14}-carbocyclyl)$, $-C_3-C_{14}-carbocyclyl$, $-(C_1-C_6-alkyl)(C_3-C_{14}-carbocyclyl)$, $C_6-C_{10}-aryl$, 3- to 14-membered heterocycloalkyl and $-(C_1-C_6-alkyl)-(3- to 14-membered heterocycloalkyl)$ (wherein 1-4 heterocycloalkyl members are independently selected from N, O, and S), and 5- to 10-membered heteroaryl (wherein 1-4 heteroaryl members are independently selected from N, O, and S);

wherein each alkyl, alkoxy, alkenyl, alkynyl, aryl, carbocyclyl,

heterocycloalkyl, and heteroaryl moiety of R^A and R^B is

optionally substituted with one or more substituents selected from the group consisting of $hydroxy$, $halo$, $-NR'^2$ (wherein each R' is independently selected from the group consisting of $C_1-C_6-alkyl$, $C_2-C_6-alkenyl$, $C_2-C_6-alkynyl$, $C_6-C_{10}-aryl$, 3- to 14-membered heterocycloalkyl and $-(C_1-C_6-alkyl)-(3- to 14-membered heterocycloalkyl)$ (wherein 1-4 ring members are independently selected from N, O, and S), and 5- to 10-membered heteroaryl (wherein 1-4 heteroaryl members are independently selected from N, O, and S), $-NHC(O)(OC_1-C_6-alkyl)$, $-NO_2$, $-CN$, oxo , $-C(O)OH$, $-C(O)O(C_1-C_6-alkyl)$, $-C_1-C_6-alkyl(C_1-C_6-alkoxy)$, $-C(O)NH_2$, $C_1-C_6-alkyl$, $-C(O)C_1-C_6-alkyl$, $-OC_1-C_6-alkyl$, $-Si(C_1-C_6-alkyl)_3$, $-S(O)_{0-2}-(C_1-C_6-alkyl)$, $C_6-C_{10}-aryl$, $-(C_1-C_6-alkyl)(C_6-C_{10}-aryl)$, 3- to 14-membered heterocycloalkyl, and $-(C_1-C_6-alkyl)-(3- to 14-membered heterocycle)$ (wherein 1-4

heterocycle members are independently selected from N, O, and S), and -O(C₆-C₁₄-aryl),

wherein each alkyl, alkenyl, aryl, and heterocycloalkyl in R^A and R^B is optionally substituted with one or more substituents selected from the group consisting of hydroxy, -OC₁-C₆-alkyl, halo, -NH₂, -(C₁-C₆-alkyl)NH₂, -C(O)OH, CN, and oxo,


or a pharmaceutically acceptable salt thereof.

2. The compound or pharmaceutically acceptable salt thereof according to claim 1, wherein


R^{2a} is absent; and

each bond == (a) represents a double bond and each bond == (b) represents a single bond.


3. The compound or pharmaceutically acceptable salt thereof according to claim 2, wherein the compound has a structure according to Formula (IA):



4. The compound or pharmaceutically acceptable salt thereof according to claim 2, wherein the compound has a structure according to Formula (IB):



5. A compound or pharmaceutically acceptable salt thereof according to Formula II:



wherein

L is O, S, NR, or a bond;

R is H or C₁-C₆-alkyl;

R^1 is selected from the group consisting of C₁-C₆-alkyl, C₂-C₆-alkenyl, C₃-C₆-carbocyclyl, -(C₁-C₆-alkyl)(C₃-C₆-carbocyclyl), and -(C₁-C₆-alkyl)(C₃-C₆-cycloalkenyl) wherein

any alkyl in R^1 is straight or branched, and

R^1 is optionally substituted by 1 – 6 halo;

or when L is NR, then R and R^1 in combination with L represent a 3- to 6-membered heterocycloalkyl (wherein 1-4 ring members are independently selected from N, O, and S) optionally substituted by one or more R^A ;

R^2 and R^3 are independently selected from the group consisting of C₆-C₁₀-aryl, 5- to 10-membered heteroaryl (wherein 1-4 heteroaryl members are independently selected from N, O, and S), and 3- to 14-membered heterocycloalkyl (wherein 1-4 heterocycloalkyl members are independently selected from N, O, and S),

wherein R^2 and R^3 are independently and optionally substituted by one or more substituents that are selected from the group consisting of R^A , OR^A , halo, -N=N- R^A , $NR^A R^B$, -(C₁-C₆-alkyl) $NR^A R^B$, -C(O) OR^A , -C(O) $NR^A R^B$, -OC(O) R^A , and -CN;

R^4 and R^6 are independently selected from the group consisting of R^A , OR^A , halo, $NR^A R^B$, -(C₁-C₆-alkyl) $NR^A R^B$, -C(O) OR^A , -C(O) $NR^A R^B$, and -OC(O) R^A ;

R^A and R^B are independently selected from the group consisting of H, -CN, -hydroxy, oxo, C₁-C₆-alkyl, C₁-C₆-alkoxy, C₂-C₆-alkenyl, C₂-C₆-alkynyl, NH₂, -S(O)₀₋₂-(C₁-C₆-alkyl), -S(O)₀₋₂-(C₆-C₁₀-aryl), -C(O)(C₁-C₆-alkyl), -C(O)(C₃-C₁₄-carbocyclyl), -C₃-C₁₄-carbocyclyl, -(C₁-C₆-alkyl)(C₃-C₁₄-carbocyclyl), C₆-C₁₀-aryl, 3- to 14-membered heterocycloalkyl and -(C₁-C₆-alkyl)-(3- to 14-membered heterocycloalkyl) (wherein 1-4 heterocycloalkyl members are independently selected from N, O, and S), and 5- to 10-membered heteroaryl (wherein 1-4 heteroaryl members are independently selected from N, O, and S);

wherein each alkyl, alkoxy, alkenyl, alkynyl, aryl, carbocyclyl, heterocycloalkyl, and heteroaryl moiety of R^A and R^B is optionally substituted with one or more substituents selected from the group consisting of hydroxy, halo, -NR'₂ (wherein each R' is

independently selected from the group consisting of C₁-C₆-alkyl, C₂-C₆-alkenyl, C₂-C₆-alkynyl, C₆-C₁₀-aryl, 3- to 14-membered heterocycloalkyl and -(C₁-C₆-alkyl)-(3- to 14-membered heterocycloalkyl) (wherein 1-4 ring members are independently selected from N, O, and S), and 5- to 10-membered heteroaryl (wherein 1-4 heteroaryl members are independently selected from N, O, and S), -NHC(O)(OC₁-C₆-alkyl), -NO₂, -CN, oxo, -C(O)OH, -C(O)O(C₁-C₆-alkyl), -C₁-C₆-alkyl(C₁-C₆-alkoxy), -C(O)NH₂, C₁-C₆-alkyl, -C(O)C₁-C₆-alkyl, -OC₁-C₆-alkyl, -Si(C₁-C₆-alkyl)₃, -S(O)₀₋₂-(C₁-C₆-alkyl), C₆-C₁₀-aryl, -(C₁-C₆-alkyl)(C₆-C₁₀-aryl), 3- to 14-membered heterocycloalkyl, and -(C₁-C₆-alkyl)-(3- to 14-membered heterocycle) (wherein 1-4 heterocycle members are independently selected from N, O, and S), and -O(C₆-C₁₄-aryl),

wherein each alkyl, alkenyl, aryl, and heterocycloalkyl in R^A and R^B is optionally substituted with one or more substituents selected from the group consisting of hydroxy, -OC₁-C₆-alkyl, halo, -NH₂, -(C₁-C₆-alkyl)NH₂, -C(O)OH, CN, and oxo,







or a pharmaceutically acceptable salt thereof.











6. The compound or pharmaceutically acceptable salt thereof according to any one of claims 1 – 5, wherein each of R⁴, R⁵, and R⁶ (if present) is independently selected from the group consisting of H, C₁-C₆-alkyl, and C₁-C₆-alkoxy.
7. The compound or pharmaceutically acceptable salt thereof according to any one of claims 1 to 6, wherein at least one of R⁴, R⁵, and R⁶ (if present) is H.
8. The compound or pharmaceutically acceptable salt thereof according to any one of claims 1 to 7, wherein R⁴ is H.
9. The compound or pharmaceutically acceptable salt thereof according to any one of claims 1 to 7, wherein R⁵ is H.
10. The compound or pharmaceutically acceptable salt thereof according to any one of claims 1 to 7, wherein R⁶ is H.







11. The compound or pharmaceutically acceptable salt thereof according to any one of claims 1 to 10, wherein each of R⁴, R⁵, and R⁶ (if present) is H.
12. The compound according to any one of claims 1 to 7, wherein R² is C₆-C₁₀-aryl or 5- to 10-membered heteroaryl.
13. The compound or pharmaceutically acceptable salt thereof according to claim 12, wherein R² is C₆-C₁₀-aryl.
14. The compound or pharmaceutically acceptable salt thereof according to claim 13, wherein R² is phenyl.
15. The compound or pharmaceutically acceptable salt thereof according to claim 12, wherein R² is 5- to 10-membered heteroaryl, and wherein 1 ring member is N.
16. The compound or pharmaceutically acceptable salt thereof according to claim 15, wherein R² is pyridyl.
17. The compound or pharmaceutically acceptable salt thereof according to any one of claims 1 to 16, wherein R³ is 3- to 14-membered heterocycloalkyl or 5- to 10-membered heteroaryl.
18. The compound or pharmaceutically acceptable salt thereof according to claim 17, wherein R³ is selected from the group consisting of benzothiazolyl, benzoisothiazolyl, benzoxazolyl, pyridinyl, pyridinonyl, benzimidazolyl, benzotriazolyl, indazolyl, quinoxaliny, quinolinyl, quinazolinyl, imidazopyridinyl, pyrazolopyridinyl, cinnolinyl, isoxazolyl, pyrazolyl, benzofuranyl, dihydrobenzofuranyl, and tetrahydrobenzodioxinyl.
19. The compound or pharmaceutically acceptable salt thereof according to any one of claims 1 to 16, wherein R³ is C₆-C₁₀-aryl.
20. The compound or pharmaceutically acceptable salt thereof according to any one of claims 1 to 19, wherein L is O or NR.
21. The compound or pharmaceutically acceptable salt thereof according to claim 20, wherein R¹ is C₁-C₆-alkyl or C₃-C₆-carbocyclyl.
22. The compound or pharmaceutically acceptable salt thereof according to claim 20 or 21, wherein R¹ is C₁-C₃-alkyl that is optionally substituted by 1 – 3 F.

23. The compound or pharmaceutically acceptable salt thereof according to any one of claims 2 – 5, wherein
- L is O or NR and R is H;
- R¹ is C₁-C₃-alkyl that is optionally substituted by 1 – 3 F;
- R² is 3- to 14-membered heterocycloalkyl or 5- to 10-membered heteroaryl (wherein 1 heterocycloalkyl or heteroaryl member is N) or C₆-C₁₀-aryl;
- R³ is 3- to 14-membered heterocycloalkyl or 5- to 10-membered heteroaryl wherein 1 to 3 heterocycloalkyl or heteroaryl members are independently selected from N, O, and S; and
- each of R⁴, R⁵, and R⁶ (if present) is H.
24. The compound or pharmaceutically acceptable salt thereof according to claim 23, wherein L is NR.
25. The compound or pharmaceutically acceptable salt thereof according to claim 1, wherein
- R^{2a} is present and it is taken together with R² and the carbon atom to which they are attached to form a spiro-fused 5- to 6-membered carbocyclyl or heterocycloalkyl (wherein 1-4 heterocycloalkyl members are independently selected from N, O, and S), each bond $\equiv$ (a) represents a single bond and each bond $\equiv$ (b) represents a double bond; and
- wherein the spiro-fused 5- to 6-membered carbocyclyl or heterocycloalkyl is optionally substituted by one or more R^A.
26. The compound or pharmaceutically acceptable salt thereof according to claim 24, wherein R^{2a}, R², and the carbon atom to which they are attached form a spiro-fused 5-membered heterocycloalkyl, wherein 1 heterocycloalkyl member is N.
27. The compound or pharmaceutically acceptable salt thereof according to claim 24, wherein R^{2a}, R², and the carbon atom to which they are attached are taken together to form a spiro-fused 6-membered heterocycloalkyl, wherein 1 heterocycloalkyl member is N.
28. The compound or pharmaceutically acceptable salt thereof according to claim 24, wherein R^{2a}, R², and the carbon atom to which they are attached are taken together to form a spiro-fused 6-membered carbocyclyl.

29. The compound or pharmaceutically acceptable salt thereof according to any one of claims 24 to 28, wherein X is N.
30. The compound or pharmaceutically acceptable salt thereof according to any one of claims 24 to 29, wherein each of R⁴ and R⁵ is independently selected from the group consisting of H, C₁-C₆-alkyl, and C₁-C₆-alkoxy.
31. The compound or pharmaceutically acceptable salt thereof according to any one of claims 24 to 30, wherein each of R⁴ and R⁵ is H.
32. The compound or pharmaceutically acceptable salt thereof according to any one of claims 24 to 31, wherein R³ is 5- to 10-membered heteroaryl wherein 2 heteroaryl members are independently selected from N, O, and S.
33. The compound or pharmaceutically acceptable salt thereof according to any one of claims 24 to 30, wherein R³ is C₆-C₁₀-aryl.
34. The compound according to claim 1, wherein the compound is selected from the following table:



101		102	
103		104	
105		106	











107		108	
109		110	
111		112	
113		114	
115		116	











117		118	
119		120	
121		122	











or a pharmaceutically acceptable salt thereof.











35. The compound according to claim 1, wherein the compound is selected from the following table:











123		124	
-----	---	-----	--











125		126	
127		128	
129		130	
131		132	
133		134	











135		136	
137		138	
139		140	
141		142	
143		144	









145		146	
147		148	
149		150	
151		152	
153		154	







155		156	
157		158	
159		160	
161		162	
163		164	

165		166	
167		168	
169		170	
171		172	
173		174	

175		176	
177		178	
179		180	
181		182	
183		184	



185		186	
187		188	
189		190	
191		192	
193		194	









195		196	
197		198	
199		200	
201		202	









203		204	
205		206	
207		208	











or a pharmaceutically acceptable salt thereof.











36. The compound according to claim 1, wherein the compound is selected from the following table:











209		210	
-----	---	-----	--











211		212	
213		214	
215		216	
217		218	









219		220	
221		222	
223		224	
225		226	

227		228	
229		230	
231		232	
233		234	
235		236	

237		238	
239		240	
241		242	
243		244	
245		246	

247		248	
249		250	
251		252	
253		254	
255		256	













257		258	
259		260	
261		262	
263		264	
265		266	











267		268	
269		270	
271		272	
273		274	



or a pharmaceutically acceptable salt thereof.

37. The compound according to claim 1, wherein the compound is selected from the following table:

101-A		102-A	
103-A		104-A	
105-A		106-A	
107-A		108-A	
109-A		110-A	
111-A		112-A	
113-A		114-A	











115-A		116-A	
117-A		118-A	
119-A		120-A	
121-A		122-A	
123-A		124-A	
125-A		126-A	


127-A		128-A	
129-A		130-A	
131-A		132-A	
133-A		134-A	
135-A		136-A	

137-A		138-A	
-------	---	-------	--

or a pharmaceutically acceptable salt thereof.

38. The compound according to claim 5, wherein the compound is selected from the following table:

139-A		140-A	
141-A		142-A	
143-A		144-A	
145-A		146-A	
147-A		148-A	



or a pharmaceutically acceptable salt thereof.

39. A pharmaceutical composition comprising a therapeutically effective amount of a compound according to any one of claims 1 to 38 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
40. A method for treating a cancer in a subject suffering therefrom, comprising administering to the subject an effective amount of a MAT2A inhibitor.
41. The method according to claim 40, wherein the cancer is an MTAP-deleted cancer.
42. A method for inhibiting the synthesis of S-adenosyl methionine (SAM) in a cell, comprising introducing into the cell an effective amount of a compound, or a pharmaceutically acceptable salt thereof, according to any one of claims 1 to 38.
43. A method for inhibiting the synthesis of S-adenosyl methionine (SAM) in a subject, comprising administering to the subject an effective amount of at least one compound or a salt thereof according to any one of claims 1 to 38.
44. A method for treating a cancer in a subject suffering therefrom, comprising administering to the subject an effective amount of a compound according to any one of claims 1 to 38.
45. The method according to claim 44, wherein the cancer is an MTAP-deleted cancer.
46. The method according to claim 40, 44, or 45, wherein the cancer is selected from the group consisting of mesothelioma, neuroblastoma, rectum carcinoma, colon carcinoma, familial adenomatous polyposis carcinoma and hereditary non-polyposis colorectal cancer, esophageal carcinoma, labial carcinoma, larynx carcinoma, hypopharynx carcinoma, tongue carcinoma, salivary gland carcinoma, gastric carcinoma,

adenocarcinoma, medullary thyroid carcinoma, papillary thyroid carcinoma, renal carcinoma, kidney parenchym carcinoma, ovarian carcinoma, cervix carcinoma, uterine corpus carcinoma, endometrium carcinoma, chorion carcinoma, pancreatic carcinoma, prostate carcinoma, bladder carcinoma, testis carcinoma, breast carcinoma, urinary carcinoma, melanoma, brain tumors, lymphoma, head and neck cancer, acute lymphatic leukemia (ALL), chronic lymphatic leukemia (CLL), acute myeloid leukemia (AML), chronic myeloid leukemia (CML), hepatocellular carcinoma, gall bladder carcinoma, bronchial carcinoma, small cell lung carcinoma, non-small cell lung carcinoma, multiple myeloma, basalioma, teratoma, retinoblastoma, choroidea melanoma, seminoma, rhabdomyo sarcoma, osteosarcoma, chondrosarcoma, myosarcoma, liposarcoma, fibrosarcoma, Ewing sarcoma, and plasmocytoma.

47. The method according to claims 40, 44 or 45, wherein the cancer is selected from the group consisting of B-cell acute lymphocytic leukemia (B-ALL), mesothelioma, lymphoma, pancreatic carcinoma, lung cancer, gastric cancer, esophageal cancer, bladder carcinoma, brain cancer, head and neck cancer, melanoma, and breast cancer.
48. The method according to claim 47, wherein the lung cancer is selected from the group consisting of non-small cell lung cancer, small cell lung cancer, adenocarcinoma of the lung, and squamous cell carcinoma of the lung.
49. The method according to claim 47, wherein the brain cancer is a brain tumor selected from the group consisting of glioma, glioblastoma, astrocytoma, meningioma, medulloblastoma, peripheral neuroectodermal tumors, and craniopharyngioma.
50. The method according to claim 47, wherein the breast cancer is triple negative breast cancer (TNBC).
51. The method according to claim 47, wherein the cancer is a lymphoma selected from the group consisting of mantle cell lymphoma, Hodgkin lymphoma, non-Hodgkin lymphoma, Burkitt lymphoma, diffuse large B-cell lymphoma, and adult T-cell leukemia/lymphoma.

52. A method for treating a cancer in a subject suffering therefrom, wherein the cancer is characterized by a reduction or absence of methylthioadenosine phosphorylase (MTAP) gene expression, the absence of the MTAP gene, or reduced function of MTAP protein, as compared to cancers where the MTAP gene or protein is present and/or fully functioning, the method comprising administering to the subject a therapeutically effective amount of a compound, or a pharmaceutically acceptable salt thereof, according to any one of claims 1 to 38.
53. A compound according to any one of claims 1 to 38, or a pharmaceutically acceptable salt thereof, for use in inhibiting the synthesis of S-adenosyl methionine (SAM).
54. A compound according to any one of claims 1 to 38, or a pharmaceutically acceptable salt thereof, for use in treating a cancer in a subject suffering therefrom.
55. The compound according to claim 54, wherein the cancer is an MTAP-deleted cancer.
56. The compound according to claim 54 or 55, wherein the cancer is selected from the group consisting of mesothelioma, neuroblastoma, rectum carcinoma, colon carcinoma, familial adenomatous polyposis carcinoma and hereditary non-polyposis colorectal cancer, esophageal carcinoma, labial carcinoma, larynx carcinoma, hypopharynx carcinoma, tongue carcinoma, salivary gland carcinoma, gastric carcinoma, adenocarcinoma, medullary thyroid carcinoma, papillary thyroid carcinoma, renal carcinoma, kidney parenchyma carcinoma, ovarian carcinoma, cervix carcinoma, uterine corpus carcinoma, endometrium carcinoma, chorion carcinoma, pancreatic carcinoma, prostate carcinoma, bladder carcinoma, testis carcinoma, breast carcinoma, urinary carcinoma, melanoma, brain tumors, lymphoma, head and neck cancer, acute lymphatic leukemia (ALL), chronic lymphatic leukemia (CLL), acute myeloid leukemia (AML), chronic myeloid leukemia (CML), hepatocellular carcinoma, gall bladder carcinoma, bronchial carcinoma, small cell lung carcinoma, non-small cell lung carcinoma, multiple myeloma, basaloma, teratoma, retinoblastoma, choroid melanoma, seminoma, rhabdomyosarcoma, osteosarcoma, chondrosarcoma,

- myosarcoma, liposarcoma, fibrosarcoma, Ewing sarcoma, and plasmocytoma.
57. The compound according to claim 54 or 55, wherein the cancer is selected from the group consisting of B-cell acute lymphocytic leukemia (B-ALL), mesothelioma, lymphoma, pancreatic carcinoma, lung cancer, gastric cancer, esophageal cancer, bladder carcinoma, brain cancer, head and neck cancer, melanoma, and breast cancer.
58. The compound according to claim 57, wherein the lung cancer is selected from the group consisting of non-small cell lung cancer, small cell lung cancer, adenocarcinoma of the lung, and squamous cell carcinoma of the lung.
59. The compound according to claim 57, wherein the breast cancer is triple negative breast cancer (TNBC).
60. The compound according to claim 57, wherein the brain cancer is a brain tumor selected from the group consisting of glioma, glioblastoma, astrocytoma, meningioma, medulloblastoma, peripheral neuroectodermal tumors, and craniopharyngioma.
61. The compound according to claim 54 or 55, wherein the cancer is a lymphoma selected from the group consisting of mantle cell lymphoma, Hodgkin lymphoma, non-Hodgkin lymphoma, Burkitt lymphoma, diffuse large B-cell lymphoma (DLBCL), and adult T-cell leukemia/lymphoma.